Holen Sie sich die Stockscreener-App
8.29
0.73%
0.06
Handel nachbörslich:
8.24
-0.05
-0.60%
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Morgan Stanley (NASDAQ: OCUL) files Rule 144 notice to sell 1,858 shares - Stock Titan
Company (NASDAQ: OCUL) files Form 144 to sell 2,967 shares - Stock Titan
OCUL (NASDAQ: OCUL) files Form 144 proposing sale of 3,018 shares - Stock Titan
Rule 144 notice for 21,156 shares — OCUL (OCUL) - Stock Titan
Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Q3 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus
Q2 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Moomoo
Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions? - simplywall.st
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Globe and Mail
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Motley Fool
Why (OCUL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
[SCHEDULE 13G/A] OCULAR THERAPEUTIX, INC Amended Passive Investment Disclosure - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New HR boss at Ocular Therapeutix lands 75,000 stock options, 25,000 RSUs - Stock Titan
Dole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market session - MSN
Neuropathic Ocular Pain Therapeutics Market Size (7MM) - openPR.com
Ocular Therapeutix, Inc. $OCUL Shares Bought by Empire Life Investments Inc. - MarketBeat
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's P - Benzinga
Ocular Therapeutix prices $475M stock offering - MSN
Ocular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA plan - MSN
Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(C)(4) - TradingView
Twelve new Ocular employees get stock awards tied to 169,200 shares - Stock Titan
Ocular Therapeutix Price Target Maintained With a $18.00/Share by Needham - Moomoo
Ocular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation Diverge - Yahoo Finance
Ocular: SOL-1 Success Is Real, But Adoption Risks Keep Me At Hold (NASDAQ:OCUL) - Seeking Alpha
Number of shareholders of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Number of shareholders of Ocular Therapeutix Inc – BX:0OT - TradingView
Ocular Therapeutix Releases 2026 First Quarter Revenue Results - VisionMonday.com
Understanding Momentum Shifts in (OCUL) - Stock Traders Daily
A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $30 - Moomoo
MSN Money - MSN
Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile Returns - Yahoo Finance
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks - TipRanks
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss By Investing.com - Investing.com India
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TipRanks
Ocular Therapeutix Q1 Earnings Call Highlights - Yahoo Finance
Ocular Therapeutix Q1 2026 earnings preview - MSN
Why Ocular Therapeutix (OCUL) Stock Is Nosediving - TradingView
Ocular Therapeutix Q1 2026 Earnings Call Transcript - MarketBeat
OCUL: AXPAXLI's phase III success in wet AMD drives NDA plans and commercial readiness, backed by strong cash reserves - TradingView
Ocular Therapeutix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ocular Therapeutix's Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss - Investing.com
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips - ChartMill
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):